Yield10 Bioscience announced that USDA-APHIS’s Biotechnology Regulatory Services has determined that Yield10’s Camelina sativa varieties developed using genetic engineering to produce omega-3 fatty acids are not subject to the regulations under 7 CFR part 340, and may be grown and bred in the United States. “This regulatory milestone represents a critical step for enabling the ramp-up of Camelina planting to commercial scale in the U.S for producing omega-3 oil for key markets including aquafeed and human nutrition,” said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. “In 2024, we plan to focus on executing our development program, building seed inventory in anticipation of commercial scale planting, and engaging with potential commercial partners to enable commercial sale of omega-3 oil and meal in target markets. Use of omega-3 oil in target markets may still be subject to regulation from other regulatory authorities in target geographies.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on YTEN:
- Is YTEN a Buy, Before Earnings?
- Yield10 Bioscience reports on proprietary varieties of winter camilina
- Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests
- Yield10 Bioscience Granted Extension to Meet Nasdaq Criteria
- Yield10 Bioscience Licenses Trait Tech for Biofuel Boost